Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Astellas Gets U.S. Clearance For Antibiotic After Some FDA Troubles

This article was originally published in PharmAsia News

Executive Summary

Astellas Pharma says it has received clearance from the U.S. FDA for its Vibativ (televancin) antibiotic. Atellas plans to launch the drug, which it developed jointly with U.S.-based Theravance, by the end of the year. Atellas considers the drug a key one for its portfolio, particularly at a time when it has experienced problems getting some of its drugs approved by the U.S. agency. Vibativ is a once-daily injectable antibiotic for treating complicated skin infections. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts